The only relevance of the first article was in the table - in light of some prior board commentary.

Someone on the board had speculated that Pfizer's candidate might be Apabetalone.

But a Pfizer candidate is listed on the table, and is not Apabetalone.

Also - that - at least in that group of reported studies, Ap was not included anywhere.

So - negative information still being information - I figured I'd share.